Barkley PMHNP Certification Examination Preparation
Study Guide: Comprehensive 150-Question Practice
Exam V2.0 with Expert Rationales for Advanced
Psychiatric-Mental Health Nurse Practitioner Board
Certification Success a well detailed one
written and graded A+ upgraded
Instructions
This comprehensive practice examination consists of 150 multiple-choice questions designed to
mirror the difficulty, format, and content distribution of the ANCC PMHNP-BC certification
examination. Questions are written at an advanced/hard difficulty level and target PMHNP
students and professionals preparing for board certification. Each question includes one correct
answer with a detailed rationale explaining both the correct choice and why the distractors are
incorrect. The examination covers all five ANCC PMHNP domains: Scientific Foundation,
Advanced Practice Skills, Diagnosis and Treatment, Psychotherapy and Related Therapies, and
Ethical and Legal Principles.
Section I: Scientific Foundation (Questions 1–30)
1. A 45-year-old male with major depressive disorder has failed multiple antidepressant trials.
Genetic testing reveals a polymorphism in the serotonin transporter gene (5-HTTLPR). Which
of the following best describes how this genetic variant affects antidepressant response?
A. The short allele is associated with reduced serotonin transporter expression and poorer
response to SSRIs
B. The long allele is associated with increased serotonin transporter expression and improved
response to SSRIs
,C. The short allele is associated with increased serotonin transporter expression and poorer
response to SSRIs
D. The long allele is associated with reduced serotonin transporter expression and improved
response to SSRIs
Correct Answer: A
Rationale: The short allele of the 5-HTTLPR polymorphism is associated with reduced serotonin
transporter expression, leading to higher synaptic serotonin levels but also poorer response to
SSRIs. This variant is associated with increased amygdala reactivity and vulnerability to stress.
Option B is incorrect because the long allele is associated with better response to SSRIs, not
improved response. Option C is incorrect because the short allele is associated with reduced,
not increased, transporter expression. Option D is incorrect because the long allele is associated
with increased transporter expression.
2. A 38-year-old female with bipolar disorder is started on lamotrigine. Which of the following
best describes the primary mechanism of action of lamotrigine in bipolar disorder?
A. Voltage-gated sodium channel blockade with glutamate release inhibition
B. Dopamine D2 receptor antagonism
C. Serotonin reuptake inhibition
D. GABA-A receptor agonism
Correct Answer: A
Rationale: Lamotrigine stabilizes mood through voltage-gated sodium channel blockade, which
inhibits the release of glutamate, an excitatory neurotransmitter. This mechanism is thought to
be responsible for its efficacy in preventing depressive episodes in bipolar disorder. Option B
describes antipsychotic mechanisms. Option C describes SSRIs. Option D describes
benzodiazepine mechanisms.
3. A 62-year-old male with Parkinson's disease develops visual hallucinations and is started on
pimavanserin. Which of the following best describes the mechanism of action of this
medication?
A. Inverse agonism at serotonin 5-HT2A receptors
B. Dopamine D2 receptor antagonism
C. Acetylcholinesterase inhibition
D. NMDA receptor antagonism
,Correct Answer: A
Rationale: Pimavanserin is a selective inverse agonist at serotonin 5-HT2A receptors, which
reduces hallucinations in Parkinson's disease psychosis without blocking dopamine D2 receptors
and worsening motor symptoms. Option B describes typical antipsychotics which would worsen
Parkinson's symptoms. Option C describes cholinesterase inhibitors. Option D describes
memantine.
4. A 29-year-old male with schizophrenia is started on cariprazine. Which of the following
receptor-binding profiles best describes this medication?
A. Partial agonism at dopamine D2 and D3 receptors with partial agonism at 5-HT1A receptors
B. Full antagonism at dopamine D2 and 5-HT2A receptors
C. Partial agonism at dopamine D2 receptors with full antagonism at 5-HT2A receptors
D. Full agonism at dopamine D2 receptors with antagonism at 5-HT2A receptors
Correct Answer: A
Rationale: Cariprazine is a partial agonist at dopamine D2 and D3 receptors and a partial agonist
at 5-HT1A receptors. Its high affinity for D3 receptors is thought to contribute to its efficacy for
negative symptoms. Option B describes typical antipsychotics. Option C describes aripiprazole's
profile but without the 5-HT1A agonism. Option D is incorrect; cariprazine is a partial agonist,
not a full agonist.
5. A 33-year-old female with generalized anxiety disorder is prescribed hydroxyzine. Which of
the following best describes the mechanism of action of this medication?
A. Central H1 receptor antagonism with anxiolytic and sedative effects
B. Serotonin 5-HT1A receptor partial agonism
C. GABA-A receptor positive allosteric modulation
D. Alpha-2 adrenergic receptor antagonism
Correct Answer: A
Rationale: Hydroxyzine is a histamine H1 receptor antagonist that crosses the blood-brain
barrier, producing anxiolytic and sedative effects. It is FDA-approved for anxiety and is often
used as an alternative to benzodiazepines. Option B describes buspirone. Option C describes
benzodiazepines. Option D describes some antidepressants like mirtazapine.
, 6. A 41-year-old male with alcohol use disorder is started on acamprosate. Which of the
following best describes the mechanism of action of this medication?
A. Modulation of glutamate and GABA systems to reduce alcohol craving
B. Mu-opioid receptor antagonism
C. Aldehyde dehydrogenase inhibition
D. Dopamine D2 receptor antagonism
Correct Answer: A
Rationale: Acamprosate modulates glutamate and GABA neurotransmitter systems, reducing
the hyperglutamatergic state that occurs during alcohol withdrawal and reducing alcohol
craving. Option B describes naltrexone. Option C describes disulfiram. Option D describes
antipsychotic medications.
7. A 27-year-old female with treatment-resistant depression is being evaluated for a
medication that acts on the glutamatergic system. Which of the following best describes the
mechanism of action of esketamine?
A. Non-competitive NMDA receptor antagonism with AMPA receptor potentiation
B. Competitive NMDA receptor antagonism
C. AMPA receptor antagonism with NMDA receptor potentiation
D. Glycine site agonism at NMDA receptors
Correct Answer: A
Rationale: Esketamine is a non-competitive NMDA receptor antagonist that leads to increased
AMPA receptor activation and downstream neuroplasticity, producing rapid antidepressant
effects. Option B describes competitive NMDA antagonists. Option C is incorrect; esketamine
antagonizes NMDA receptors and potentiates AMPA signaling. Option D describes a different
mechanism.
8. A 55-year-old male with vascular dementia is started on a medication that improves
cerebral blood flow. Which of the following best describes the mechanism of action of
nicergoline?
A. Alpha-1 adrenergic receptor antagonism with improved cerebral metabolism
B. Calcium channel blockade with vasodilation
C. Acetylcholinesterase inhibition
D. NMDA receptor antagonism
Study Guide: Comprehensive 150-Question Practice
Exam V2.0 with Expert Rationales for Advanced
Psychiatric-Mental Health Nurse Practitioner Board
Certification Success a well detailed one
written and graded A+ upgraded
Instructions
This comprehensive practice examination consists of 150 multiple-choice questions designed to
mirror the difficulty, format, and content distribution of the ANCC PMHNP-BC certification
examination. Questions are written at an advanced/hard difficulty level and target PMHNP
students and professionals preparing for board certification. Each question includes one correct
answer with a detailed rationale explaining both the correct choice and why the distractors are
incorrect. The examination covers all five ANCC PMHNP domains: Scientific Foundation,
Advanced Practice Skills, Diagnosis and Treatment, Psychotherapy and Related Therapies, and
Ethical and Legal Principles.
Section I: Scientific Foundation (Questions 1–30)
1. A 45-year-old male with major depressive disorder has failed multiple antidepressant trials.
Genetic testing reveals a polymorphism in the serotonin transporter gene (5-HTTLPR). Which
of the following best describes how this genetic variant affects antidepressant response?
A. The short allele is associated with reduced serotonin transporter expression and poorer
response to SSRIs
B. The long allele is associated with increased serotonin transporter expression and improved
response to SSRIs
,C. The short allele is associated with increased serotonin transporter expression and poorer
response to SSRIs
D. The long allele is associated with reduced serotonin transporter expression and improved
response to SSRIs
Correct Answer: A
Rationale: The short allele of the 5-HTTLPR polymorphism is associated with reduced serotonin
transporter expression, leading to higher synaptic serotonin levels but also poorer response to
SSRIs. This variant is associated with increased amygdala reactivity and vulnerability to stress.
Option B is incorrect because the long allele is associated with better response to SSRIs, not
improved response. Option C is incorrect because the short allele is associated with reduced,
not increased, transporter expression. Option D is incorrect because the long allele is associated
with increased transporter expression.
2. A 38-year-old female with bipolar disorder is started on lamotrigine. Which of the following
best describes the primary mechanism of action of lamotrigine in bipolar disorder?
A. Voltage-gated sodium channel blockade with glutamate release inhibition
B. Dopamine D2 receptor antagonism
C. Serotonin reuptake inhibition
D. GABA-A receptor agonism
Correct Answer: A
Rationale: Lamotrigine stabilizes mood through voltage-gated sodium channel blockade, which
inhibits the release of glutamate, an excitatory neurotransmitter. This mechanism is thought to
be responsible for its efficacy in preventing depressive episodes in bipolar disorder. Option B
describes antipsychotic mechanisms. Option C describes SSRIs. Option D describes
benzodiazepine mechanisms.
3. A 62-year-old male with Parkinson's disease develops visual hallucinations and is started on
pimavanserin. Which of the following best describes the mechanism of action of this
medication?
A. Inverse agonism at serotonin 5-HT2A receptors
B. Dopamine D2 receptor antagonism
C. Acetylcholinesterase inhibition
D. NMDA receptor antagonism
,Correct Answer: A
Rationale: Pimavanserin is a selective inverse agonist at serotonin 5-HT2A receptors, which
reduces hallucinations in Parkinson's disease psychosis without blocking dopamine D2 receptors
and worsening motor symptoms. Option B describes typical antipsychotics which would worsen
Parkinson's symptoms. Option C describes cholinesterase inhibitors. Option D describes
memantine.
4. A 29-year-old male with schizophrenia is started on cariprazine. Which of the following
receptor-binding profiles best describes this medication?
A. Partial agonism at dopamine D2 and D3 receptors with partial agonism at 5-HT1A receptors
B. Full antagonism at dopamine D2 and 5-HT2A receptors
C. Partial agonism at dopamine D2 receptors with full antagonism at 5-HT2A receptors
D. Full agonism at dopamine D2 receptors with antagonism at 5-HT2A receptors
Correct Answer: A
Rationale: Cariprazine is a partial agonist at dopamine D2 and D3 receptors and a partial agonist
at 5-HT1A receptors. Its high affinity for D3 receptors is thought to contribute to its efficacy for
negative symptoms. Option B describes typical antipsychotics. Option C describes aripiprazole's
profile but without the 5-HT1A agonism. Option D is incorrect; cariprazine is a partial agonist,
not a full agonist.
5. A 33-year-old female with generalized anxiety disorder is prescribed hydroxyzine. Which of
the following best describes the mechanism of action of this medication?
A. Central H1 receptor antagonism with anxiolytic and sedative effects
B. Serotonin 5-HT1A receptor partial agonism
C. GABA-A receptor positive allosteric modulation
D. Alpha-2 adrenergic receptor antagonism
Correct Answer: A
Rationale: Hydroxyzine is a histamine H1 receptor antagonist that crosses the blood-brain
barrier, producing anxiolytic and sedative effects. It is FDA-approved for anxiety and is often
used as an alternative to benzodiazepines. Option B describes buspirone. Option C describes
benzodiazepines. Option D describes some antidepressants like mirtazapine.
, 6. A 41-year-old male with alcohol use disorder is started on acamprosate. Which of the
following best describes the mechanism of action of this medication?
A. Modulation of glutamate and GABA systems to reduce alcohol craving
B. Mu-opioid receptor antagonism
C. Aldehyde dehydrogenase inhibition
D. Dopamine D2 receptor antagonism
Correct Answer: A
Rationale: Acamprosate modulates glutamate and GABA neurotransmitter systems, reducing
the hyperglutamatergic state that occurs during alcohol withdrawal and reducing alcohol
craving. Option B describes naltrexone. Option C describes disulfiram. Option D describes
antipsychotic medications.
7. A 27-year-old female with treatment-resistant depression is being evaluated for a
medication that acts on the glutamatergic system. Which of the following best describes the
mechanism of action of esketamine?
A. Non-competitive NMDA receptor antagonism with AMPA receptor potentiation
B. Competitive NMDA receptor antagonism
C. AMPA receptor antagonism with NMDA receptor potentiation
D. Glycine site agonism at NMDA receptors
Correct Answer: A
Rationale: Esketamine is a non-competitive NMDA receptor antagonist that leads to increased
AMPA receptor activation and downstream neuroplasticity, producing rapid antidepressant
effects. Option B describes competitive NMDA antagonists. Option C is incorrect; esketamine
antagonizes NMDA receptors and potentiates AMPA signaling. Option D describes a different
mechanism.
8. A 55-year-old male with vascular dementia is started on a medication that improves
cerebral blood flow. Which of the following best describes the mechanism of action of
nicergoline?
A. Alpha-1 adrenergic receptor antagonism with improved cerebral metabolism
B. Calcium channel blockade with vasodilation
C. Acetylcholinesterase inhibition
D. NMDA receptor antagonism
